Biotinylated Polyclonal Antibodies

Biotinylated Anti-Human sTRAIL/Apo2L

0 ReviewsSubmit a Review

Product Details

Catalogue Number: 500-P135BT

Source: Polyclonal Rabbit

Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human sTRAIL/Apo2L. Anti-Human sTRAIL/Apo2L-specific antibody was purified by affinity chromatography and then biotinylated.

Immunogen: E.coli-derived, 19.6 kDa Recombinant Human sTRAIL/Apo2L (PeproTech catalog# 310-04)

Sandwich ELISA: To detect Human sTRAIL/Apo2L by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.25 – 1.0 μg/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with PeproTech’s Polyclonal Anti-Human sTRAIL/Apo2L (500-P135) as a capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant Human sTRAIL/Apo2L.

Biotinylated Anti-Human sTRAIL/Apo2L Sandwich ELISA

Western Blot: To detect Human sTRAIL/Apo2L by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant Human sTRAIL/Apo2L is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Biotinylated Anti-Human sTRAIL/Apo2L Western Blot Reduced Biotinylated Anti-Human sTRAIL/Apo2L Western Blot Unreduced


1mg will be provided as 2x500μg.

Country Of Origin: USA

Not for human use.

Research Interest


First Author
Mulherkar, N
MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
The Journal of Biological Chemistry; 282(16) pg11715-21
PubMed Id
First Author
Kim, C
Cancer gene therapy using a novel secretable trimeric TRAIL.
Gene Therapy; 13(4) pg330-8
PubMed Id
First Author
Jeong, M
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
PLoS ONE; 4(2) pge4545
PubMed Id